IN THE CLAIMS

A listing of the claims presented in this patent application appears below. This listing replaces all prior versions and listing of claims in this patent application.

1. (Currently Amended) The present invention relates to compounds of formula I:



I

its enantiomer, diastereomer, or pharmaceutically acceptable salt, hydrate or prodrug thereof wherein:

R_1 and R_2 independently represent

i) hydrogen,

ii) $(CH_2)_nNR_5R_6$,

iii) $CR_7R_8R_9$, $C(R)_2OR_{14}$, CH_2NHR_{14},

iv) $C(=O)R_{13}$, $C(=NOH)H$, $C(=NOR_{13})H$, $C(=NOR_{13})R_{13}$, $C(=NOH)R_{13}$, $C(=O)N(R_{13})_2$, $C(=NOH)N(R_{13})_2$, $NHC(=X_1)N(R_{13})_2$, $(C=NH)R_7$, $N(R_{13})C(=X_1)N(R_{13})_2$, $COOR_{13}$, SO_2R_{14}, $N(R_{13})SO_2R_{14}$, $N(R_{13})COR_{14}$,

v) $(C_{1\text{-}6}alkyl)CN$, CN, $CH=C(R)_2$, $(CH_2)_pOH$, $C(=O)CHR_{13}$, $C(=NR_{13})R_{13}$, $NR_{10}C(=X_1)R_{13}$; or

vi) $C_{5\text{-}10}$ heterocycle optionally substituted with 1-3 groups of R_7, which may be attached through either a carbon or a heteroatom;

R_{1a} represents $(CH_2)_nNR_5R_6$, $CR_7R_8R_9$, $C(R)_2OR_{14}$, CH_2NHR_{14},

$C(=O)R_{13}$, $C(=NOH)H$, $C(=NOR_{13})H$, $C(=NOR_{13})R_{13}$, $C(=NOH)R_{13}$, $C(=O)N(R_{13})_2$, $C(=NOH)N(R_{13})_2$, $NHC(=X_1)N(R_{13})_2$, $(C=NH)R_7$, $N(R_{13})C(=X_1)N(R_{13})_2$, $COOR_{13}$, SO_2R_{14}, $N(R_{13})SO_2R_{14}$, $N(R_{13})COR_{14}$, $(C_{1\text{-}6}alkyl)CN$, CN, $CH=C(R)_2$, $(CH_2)_pOH$, $C(=O)CHR_{13}$, $C(=NR_{13})R_{13}$, $NR_{10}C(=X_1)R_{13}$; or $C_{5\text{-}10}$ heterocycle optionally substituted with 1-3 groups of R_7, which may be attached through either a carbon or a heteroatom;

X is selected from the group consisting of,



;

Z represents $(O)_n$, H, OH, or halogen;

A represents C (when --- is present provided $Z = (O)_n$ and n=0), C (when --- is not present provided Z is H, OH or halogen), or N (when --- is not present and $Z = (O)_n$ and n=1);

--- represents a bond;



represents aryl or heteroaryl, ~~heterocycle, heterocyclyl or heterocyclic, provided that in the case of a heteroaryl, heterocycle, heterocyclyl or heterocyclic,~~ provided that in the case of a heteroaryl, a cyclopropyl is not attached to a nitrogen atom on the ring;

R_x represents hydrogen or $C_{1\text{-}6}$ alkyl;

R_3 represent

i) $NR_{13}(C=X_2)R_{12}$,

ii) $NR_{13}(C=X_1)R_{12}$,

iii) $NR_{13}SO_2R_{14}$,

iv) $N(R_{13})$heteroaryl,

v) $NR_{13}(CHR_{13})_{0-4}$aryl,

vi) $NR_{13}(CHR_{13})_{0-4}$heteroaryl,

vii) $S(CHR_{13})_{0-4}$aryl,

viii) $S(CHR_{13})_{0-4}$heteroaryl,

ix) $O(CHR_{13})_{0-4}$aryl,

x) $O(CHR_{13})_{0-4}$heteroaryl,

xi) $NOH(C=X_1)R_{12}$,

xii) -OC=N(OCOaryl) C_{1-6} alkyl

xiii) -OC=N(OH) C_{1-6} alkyl

xiv) C_{5-10} heteroaryl which may be attached through either a carbon or a heteroatom; said aryl and heteroaryl optionally substituted with 1-3 groups of R_7,

R_4, R_{4a}, R_{4b}, and R_{4c} independently represent

i) hydrogen,

ii) halogen,

iii) C_{1-6} alkoxy, or

iv) C_{1-6} alkyl

r and s independently are 1-3, with the provision that when $(R_{4a})_s$ and $(R_4)_r$ or (R_{4b}) and $(R_{4c})_s$ are attached to an Ar or HAr ring the sum of r and s is less than or equal to 4;

R_5 and R_6 independently represent

i) hydrogen,

ii) C_{1-6} alkyl optionally substituted with 1-3 groups of halogen, CN, OH, C_{1-6} alkoxy, amino, imino, hydroxyamino, alkoxyamino, C_{1-6} acyloxy, C_{1-6} alkylsulfenyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyl, aminosulfonyl, C_{1-6} alkylaminosulfonyl, C_{1-6} dialkylaminosulfonyl, 4-morpholinylsulfonyl, phenyl, pyridine, 5-isoxazolyl, ethylenyloxy, or ethynyl, said phenyl and pyridine optionally substituted with 1-3 halogen, CN, OH, CF_3, C_{1-6} alkyl or C_{1-6} alkoxy;

iii) C_{1-6} acyl optionally substituted with 1-3 groups of halogen, OH, SH, C_{1-6} alkoxy, naphthalenoxy, phenoxy, amino, C_{1-6} acylamino, hydroxylamino, alkoxylamino, C_{1-6} acyloxy, aralkyloxy, phenyl, pyridine, C_{1-6} alkylcarbonyl, C_{1-6} alkylamino, C_{1-6} dialkylamino, C_{1-6} hydroxyacyloxy, C_{1-6} alkylsulfenyl, phthalimido, maleimido,

succinimido, said phenoxy, phenyl and pyridine optionally substituted with 1-3 groups of halo, OH, CN, C_{1-6} alkoxy, amino, C_{1-6} acylamino, CF_3 or C_{1-6} alkyl;

iv) C_{1-6} alkylsulfonyl optionally substituted with 1-3 groups of halogen, OH, C_{1-6} alkoxy, amino, hydroxylamino, alkoxylamino, C_{1-6} acyloxy, or phenyl; said phenyl optionally substituted with 1-3 groups of halo, OH, C_{1-6} alkoxy, amino, C_{1-6} acylamino, CF_3 or C_{1-6} alkyl;

v) arylsulfonyl optionally substituted with 1-3 of halogen, C_{1-6} alkoxy, OH or C_{1-6} alkyl;

vi) C_{1-6} alkoxycarbonyl optionally substituted with 1-3 of halogen, OH, C_{1-6} alkoxy, C_{1-6} acyloxy, or phenyl, said phenyl optionally substituted with 1-3 groups of halo, OH, C_{1-6} alkoxy, amino, C_{1-6} acylamino, CF_3 or C_{1-6} alkyl;

vii) aminocarbonyl, C_{1-6} alkylaminocarbonyl or C_{1-6} dialkylaminocarbonyl, said alkyl groups optionally substituted with 1-3 groups of halogen, OH, C_{1-6} alkoxy or phenyl

viii) five to six membered heterocycles optionally substituted with 1-3 groups of halogen, OH, CN, amino, C_{1-6} acylamino, C_{1-6} alkylsulfonylamino, C_{1-6} alkoxycarbonylamino, C_{1-6} alkoxy, C_{1-6} acyloxy or C_{1-6} alkyl, said alkyl optionally substituted with 1-3 groups of halogen, or C_{1-6} alkoxy;

ix) C_{3-6} cycloalkylcarbonyl optionally substituted with 1-3 groups of halogen, OH, C_{1-6} alkoxy or CN;

x) benzoyl optionally substituted with 1-3 groups of halogen, OH, C_{1-6} alkoxy, C_{1-6} alkyl, CF_3, C_{1-6} alkanoyl, amino or C_{1-6} acylamino;

xi) pyrrolylcarbonyl optionally substituted with 1-3 of C_{1-6} alkyl;

xii) C_{1-2} acyloxyacetyl where the acyl is optionally substituted with amino, C_{1-6} alkylamino, C_{1-6} dialkylamino, 4-morpholino, 4-aminophenyl, 4-(dialkylamino)phenyl, 4-(glycylamino)phenyl; or

R_5 and R_6 taken together with any intervening atoms can form a 3 to 7 membered heterocyclic ring containing carbon atoms and 1-2 heteroatoms independently chosen from O, S, SO, SO_2, N, or NR_8;

R_7 represent

i) hydrogen, halogen, CN, CO_2R, $CON(R)_2$, CHO, $(CH_2)_{0-3}NHAc$, C(=NOR), OH, C_{1-6} alkoxy, C_{1-6} alkyl, alkenyl, hydroxy C_{1-6} alkyl, $(CH_2)_{1-3}NHC(O)C_{1-6}$ alkyl, $(CH_2)_{0-3}N(C_{1-6}$ alkyl$)_2$

ii) $(CH_2)_n$amino, $(CH_2)_n$C1-6 alkylamino, C_{1-6} dialkylamino, hydroxylamino or C_{1-2} alkoxyamino all of which can be optionally substituted on the nitrogen with C_{1-6} acyl,

C_{1-6} alkylsulfonyl or C_{1-6} alkoxycarbonyl, said acyl and alkylsulfonyl optionally substituted with 1-2 of halogen or OH;

R_8 and R_9 independently represents

i) H, CN,

ii) C_{1-6} alkyl optionally substituted with 1-3 halogen, CN, OH, C_{1-6} alkoxy, C_{1-6} acyloxy, or amino,

iii) phenyl optionally substituted with 1-3 groups of halogen, OH, C_{1-6} alkoxy; or

R_7 and R_8 taken together can form a 3-7 membered carbon ring optionally interrupted with 1-2 heteroatoms chosen from O, S, SO, SO_2, NH, and NR_8;

X_1 represents O, S or NR_{13}, NCN, NCO_2R_{16}, or NSO_2R_{14}

X_2 represents O, S, NH or NSO_2R_{14};

R_{10} represents hydrogen, C_{1-6} alkyl or CO_2R_{15};

R_{12} represents hydrogen, C_{1-6} alkyl, NH_2, OR, CHF_2, $CHCl_2$, CR_2Cl, $(CH_2)_nSR$, $(CH_2)_nCN$, $(CH_2)_nSO_2R$, $(CH_2)_nS(O)R$, C_{1-6} alkylamino, C_{5-10} heteroaryl or C_{1-6} dialkylamino, where said alkyl may be substituted with 1-3 groups of halo, CN, OH or C_{1-6} alkoxy, said heteroaryl optionally substituted with 1-3 groups of R_7;

Each R_{13} represents independently hydrogen, C_{1-6} alkyl, C_{6-10} aryl, NR_5R_6, SR_8, $S(O)R_8$, $S(O)_2R_8$, CN, OH, C_{1-6} alkylS(O)R, C_{1-6} alkoxycarbonyl, hydroxycarbonyl, -OCOaryl, C_{1-6} acyl, C_{3-7} membered carbon ring optionally interrupted with 1-4 heteroatoms chosen from O, S, SO, SO_2, NH and NR_8 where said C_{1-6} alkyl, aryl or C_{1-6} acyl groups may be independently substituted with 0-3 halogens, hydroxy, $N(R)_2$, CO_2R, C_{6-10} aryl, C $_{5-10}$ heteroaryl, or C_{1-6} alkoxy groups;

When two R_{13} groups are attached to the same atom or two adjacent atoms they may be taken together to form a 3-7 membered carbon ring optionally interrupted with 1-2 heteroatoms chosen from O, S, SO, SO_2, NH, and NR_8;

R represents hydrogen or C_{1-6} alkyl;

R_{14} represents amino, C_{1-6} alkyl, C_{1-6} haloalkyl, five to six membered heterocycles or phenyl, said phenyl and heterocycles optionally substituted with 1-3 group of halo, C_{1-6} alkoxy, C_{1-6} acylamino, or C_{1-6} alkyl, hydroxy and/or amino, said amino and hydroxy optionally protected with an amino or hydroxy protecting group;

R_{15} is C_{1-6} alkyl or benzyl said benzyl optionally substituted with 1-3 groups of halo, OH, C_{1-6} alkoxy, amino, C_{1-6} acylamino, or C_{1-6} alkyl;

R_{16} is hydrogen, C_{5-10}heteroaryl, C_{6-10}aryl, said heteroaryl and aryl optionally substituted with 1-3 groups of R_7;

p represents 0-2 and

n represents 0-1.

2. (Original) A compound according to claim 1 wherein R_1 and R_2 independently represent H, NR_5R_6, CN, OH, $C(R)_2OR_{14}$, $NHC(=X1)N(R_{13})2$, $C(=NOH)N(R_{13})2$, $NR_{10}C(=X_1)R_{13}$ or $CR_7R_8R_9$ and R_{1a} represents NR_5R_6, CN, OH, $C(R)_2OR_{14}$, $NHC(=X1)N(R_{13})2$, $C(=NOH)N(R_{13})2$, $NR_{10}C(=X_1)R_{13}$ or $CR_7R_8R_9$.

3. (Original) A compound according to claim 2 wherein 

and 

independently are phenyl, pyridine, pyrimidine, or piperidine.

4. (Original) A compound according to claim 3 wherein when X is 

.

5. (Original) A compound according to claim 3 wherein X is



6. (Original) A compound according to claim 5 wherein A is C, --- is present and Z=$(O)_n$ where n=0, A is C, --- is not present and Z=H, OH or halogen, or A is N, --- is not present and Z=(O)n where n=1.

7. (Original) A compound according to claim 6 wherein one of R_1 and R_2 is H and the other is NR_5R_6, or H and the other is $NR_{10}C(=X_1)R_{13}$

8. (Original) A compound according to claim 4 wherein one of R_{1a} is CN, $NR_{10}C(=X_1)R_{13}$, or NR_5R_6.

9. (Original) A compound according to claim 1 wherein R_3 is $NR(C=X_1)R_{12}$, C_{5-10} heteroaryl, $NH(CH_2)_{0-4}$aryl, $NH(CH_2)_{0-4}$heteroaryl, said aryl and heteroaryl optionally substituted with 1-3 groups of Ra.

10. (Original) A compound according to claim 9 wherein R_3 is a C_{5-10} heteroaryl represented by (N) which represents an optionally substituted aromatic heterocyclic group containing 1to 4 nitrogen atoms and at least one double bond, and which is connected through a bond on any nitrogen.

11. (Original) A compound according to claim 1 wherein the structural formula is II:



Formula II

Wherein:

X is selected from the group consisting of,



Z represents $(O)_n$, H, OH, or halogen;

A represents C (when --- is present provided Z = $(O)_n$ and n=0), C (when --- is not present provided Z is H, OH or halogen), or N (when --- is not present and Z = $(O)_n$ and n=1); and R_{1a}, R_1, R_2, Rx, R_4, R_{4a}, and R_3 are as previously described herein.

12. (Original) A compound according to claim 11 wherein R_{1a} is CN or NR_5R_6.

13. (Original) A compound which is:
N-[5(S)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[5-(1-cyanocyclopropan-1-yl)pyridin-2-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[2-(1-(t-butoxycarbonyl)aminocyclopropan-1-yl)pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[2-(1-(t-butoxycarbonyl)aminocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[2-(1-(dimethylamino)methylcyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[2-(1-(dimethylamino)methylcyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[2-(1-t-butoxycarbonylcyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,

N-[5(S)-3-[4-[2-(1-hydroxymethylcyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[2-(1-hydroxycarbonylcyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride,
N-[5(S)-3-[4-[2-(1-(t-butoxycarbonyl)aminocyclopropan-1-yl)pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[2-(1-aminomethylcyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
1-[5(R)-3-[4-[2-[(1α,5α,6α)-6-(N-t-butoxycarbonyl)amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridyl-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
N-[5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]phenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one,
5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]phenyl]-5-[N-(t-butoxycarbonyl)-N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one,
5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]phenyl]-5-[N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one,
5(R)-3-[4-[2-(1-t-butoxycarbonylaminocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-5-[N-(t-butoxycarbonyl)-N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one,
5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-5-[N-(t-butoxycarbonyl)-N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one,
5(R)-3-[4-[2-(1-t-butoxycarbonylaminocyclopropan-1-yl)pyridin-5-yl]phenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one,

5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]phenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one,
5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-5-[N-(t-butoxycarbonyl)-N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one,
5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-5-[N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one,
5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one,
1-[5(R)-3-[4-[2-[(1α,5α,6α)-6-(N-t-butoxycarbonyl)amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
5(R)-3-[4-[2-[(1α,5α,6α)-6-(N-t-butoxycarbonyl)amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
5(R)-3-[4-[2-[(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
5(R)-3-[4-[2-[(1α,5α,6α)-6-(N-t-butoxycarbonyl)amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
5(R)-3-[4-[2-[(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
1-[5(R)-3-[4-[2-[(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[2-(1-t-butoxycarbonylaminocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-4-methyl-1,2,3-triazole,
1-[5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-4-methyl-1,2,3-triazole,
N-[5(S)-3-[4-[4-(1-(t-butoxycarbonyl)aminocyclopropan-1-yl)phenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[4-(1-aminocyclopropan-1-yl)phenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[4-(1-(t-butoxycarbonyl)aminocyclopropan-1-yl)phenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[4-(1-aminocyclopropan-1-yl)phenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[4-(1-(t-butoxycarbonyl)aminocyclopropan-1-yl)-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,

N-[5(S)-3-[4-[4-(1-aminocyclopropan-1-yl)-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[4-(1-(t-butoxycarbonyl)aminocyclopropan-1-yl)-3-fluorophenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[4-(1-aminocyclopropan-1-yl)-3-fluorophenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[2-(1-aminocyclopropan-1-yl)-3-fluoropyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[4-(1-aminocyclopropan-1-yl)phenyl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
N-[5(S)-3-[4-[2-(1-aminocyclopropan-1-yl)pyrimidin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,
1-[5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-4-methyl-1,2,3-triazole,
1-[5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)-3-fluoropyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-4-methyl-1,2,3-triazole,
1-[5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
or

its enantiomer, diastereomer, or pharmaceutically acceptable salt, hydrate or prodrug thereof.

14. (Original) A pharmaceutical composition comprised of a compound in accordance with claim 1 in combination with a pharmaceutically acceptable carrier and optionally a in combination with a vitamin selected from the group consisting vitamin B2, vitamin B6, vitamin B12 and folic acid.

15. (Original) A method of treating or preventing a bacterial infection in a mammalian patient in need thereof, comprising administering to said patient an effective amount of a compound of claim 1.

16. (Original) A method of treating or preventing bacterial infection or an oxazolidinone-associated side effect by administering an effective amount of a compound of formula I of claim 1 and an effective amount of one or more of a vitamin selected from the group consisting of vitamin B2, vitamin B6, vitamin B12 and folic acid to a patient in need thereof.

17. (Original) A method according to claim 16 for treating or preventing oxazolidinone-associated normocyctic anemia, peripheral sensory neuropathy, sideroblastic anemia, peripheral sensory neuropathy, optic neuropathy, seizures, thrombocytopenia, cheilosis,

hypo-regenerative anemia, megaloblastic anemia and seborrheic dermatitis by administering an effective amount of vitamin B2 to a patient in need thereof.